Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.

Exclusion Criteria

• •Patients who have smoked or inhaled tobacco products within the 6 month period prior to Visit 1
• •Patients who have had an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit within 6 weeks of Visit 1
• •Patients with narrow-angle glaucoma, symptomatic benign prostatic hyperplasia (BPH) or bladder-neck obstruction or severe renal impairment or urinary retention
• •Patients who have had a respiratory tract infection or asthma worsening within 4 weeks prior to Visit 1
• •Patients with any chronic conditions affecting the upper respiratory tract
• •Patients with a history of chronic lung diseases other than asthma, including (but not limited to) COPD, sarcoidosis, interstitial lung disease, cystic fibrosis, clinically significant bronchiectasis and active tuberculosis.
• •Patients with Type I diabetes or uncontrolled Type II diabetes (HbA1c \>9% at screening).
• •Patients who have a clinically significant ECG abnormality at Visit 1
• •Patients with a history of hypersensitivity or intolerance to any of the study drugs (including excipients)
• •Patients with narcolepsy and/or insomnia.
• •Patients on Maintenance Immunotherapy (desensitization) for allergies for less than 3 months prior to Visit 2 or patients on Maintenance Immunotherapy for more than 3 months prior to Visit 2 but expected to change throughout the course of the study.
• •Pregnant or nursing (lactating) women
• •Women of child-bearing potential must use Highly effective contraception methods
• •Patients who have discontinued LAMA therapy in the past for any safety, tolerability or perceived lack of efficacy reason.
• •History of paradoxical bronchospasm in response to inhaled medicines.
• •Patients with a history of clinically relevant bronchoconstriction upon repeated forced expiratory maneuvers.
• •Patient with a serum potassium level below the laboratory limit of normal at screening.